

Michael D Hill MD, MSc FRCPC (FAHA FESO FCAHS FRCS)
President, Canadian Neurological Sciences Federation
Professor, Dept Clinical Neuroscience & Hotchkiss Brain Institute
Senior Medical Director for Stroke, Alberta Health Services (Strategic Clinical Network)

Calgary Stroke Program
Department of Clinical Neuroscience and Hotchkiss Brain Institute
University of Calgary and Foothills Medical Centre
Rm 2939, Health Sciences Centre, 3330 Hospital Drive NW, Calgary, Alberta T2N 4N1, CANADA
P: 403.210.7786
E: michael.hill@ucalgary.ca

Training

1986-89	BSc, Biochemistry, McGill University
1989-93	MD, University of Ottawa
1993-96	FRCPC, Internal Medicine, University of Ottawa Chief Resident, Ottawa Civic Hospital
1996-99	FRCPC, Neurology, University of Toronto Chief Resident, TWH & SHSC
1999-01	Clinical Stroke Fellowship, University of Calgary
1999-03	MSc, Clinical Epidemiology, University of Calgary

Employment History

2011-present	Professor of Neurology, Department of Clinical Neurosciences, University of Calgary [Cross-appointed to the Department of Community Health Sciences, Department of Medicine, Department of Radiology]
2009-2014	Associate Dean (Clinical Research), Faculty of Medicine, University of Calgary
2005-2011	Associate Professor of Neurology, Professor of Neurology, Department of Clinical Neurosciences, University of Calgary [Cross-appointed to the Department of Community Health Sciences, Department of Medicine, Department of Radiology]
2001-2005	Assistant Professor of Neurology, Professor of Neurology, Department of Clinical Neurosciences, University of Calgary [Cross-appointed to the Department of Community Health Sciences, Department of Medicine]
2001-present	Neurology faculty. Alberta Health Services, Calgary Zone
2003-07	Neurology Visiting Faculty. Medicine Hat Regional Hospital
1997-99	Medical Staff. Toronto East General Hospital

Selected Honours/Distinctions

2021	Cumming School of Medicine's Smith Distinguished Achievement Award <i>This Award recognizes the extraordinary contribution made by you to the Cumming School of Medicine over the past two years. Such recognition is given to only a few of our faculty and is awarded to you for outstanding contributions by a senior faculty member.</i>
2020	Science Breakthrough Award. American Brain Foundation. ESCAPE Trial – awarded to Andrew Demchuk, Mayank Goyal, Michael Hill
2018	Killam Annual Professor Award
2017	Sir Paul Nurse, 2 nd Annual Lecturer in Neuroscience, AVIC Symposium. Oxford University. Awarded at Oxford, UK. Nov 23, 2017
2016	Heart & Stroke Foundation of Canada – Award of Merit. [The HSFC's highest award given in recognition of volunteer contribution to the

	foundation and its mission.]
2015	ASTECH Award 2015 for Society Impact
2015	Hnatyshyn Lecturer. Canadian Stroke Congress. Heart & Stroke Foundation, September 2015. Presented in Toronto, ON.
2013	Fellow of the Canadian Academy of Health Sciences (Elected June 2013)
2012	Heart & Stroke Foundation of Alberta/NWT/NU and HBI Professorship in Stroke Research
2012	CIHR CMAJ Top Achievements in Health Research 2012
2006	Heart & Stroke Foundation of Alberta/NWT/NU and HBI Professorship in Stroke Research
2004	Michael S. Pessin Award- American Academy of Neurology
2002	Frances McNaughton Memorial Award-Canadian Neurological Society
2001	Barnett Scholarship – Heart & Stroke Foundation of Canada

Experience Working in Collaborative Projects

ESCAPE-NA1 trial. This is a completed phase 3 randomized controlled trial to assess treatment of acute stroke with nerinetide vs. placebo. There were 48 active sites internationally in Canada, US, UK, Europe, Australia and South Korea

ESCAPE trial. This is a completed phase 3 randomized controlled trial to assess the treatment of acute stroke with endovascular therapy. There were 22 active site internationally in Canada, US, UK, Europe and South Korea.

TEMPO-2 trial. This is a current phase 3 cohort study to assess the use of TNK-TPA for the treatment of minor stroke. There 35 active sites in internationally.

ENACT trial. This was a recently completed randomized trial of NA-1 for the perioperative treatment of intracranial aneurysms and is the immediate pre-cursor to FRONTIER. There were 14 active sites in Canada and the US.

ALIAS trial. This was a recently completed randomized controlled trials of human serum albumin as a treatment for stroke. There were over 100 sites in Canada, US, Finland and Israel.

Major Grants in the Past 5 Years

1. TEMPO-2 trial. Co-Principal Investigator. \$1,992,825.00 (2018-2023). Phase 3 randomized clinical trial - A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion.. Funded by CIHR.
2. ESCAPE-NA1 trial. Principal Investigator. \$2,138,245.00 (2016-2019) from CIHR, \$13M from NoNO Inc.. Phase 3 randomized clinical trial - Extension of Stroke Care by Added neuroProtection to Endovascular Treatment (ESCAPE-NA1). CIHR project scheme grant
3. QuICR group. Principal Investigator. \$5M. 2014-2019. Program grant for Alberta to improve acute stroke care. Funded by Alberta Innovates Health Solutions.
4. ESCAPE trial. Principal Investigator. \$4M. 2013-2015. Phase 3 randomized clinical trial to examine endovascular stroke therapy led from Calgary. Consortium funding (Covidien, UofC, HBI, HSFC).
5. PROVE-IT study. Co-investigator. Prospective cohort study to examine the role of CT perfusion and multiphase CTA in the assessment of acute stroke. CIHR & HSFC. 2014-2017.

PUBLICATIONS

Peer-reviewed = 700 [Original Research Manuscripts (543), Reviews, Guidelines (78), Editorials, Opinions (79)]
 Other = 677 [Book Chapters, Reviews - *Non-peer-reviewed* (17), Abstracts, Conference Proceedings, Letters, Notes (659)]
 ISI Web of Science (27 Oct 2021) Total citations = 47271; Average Citations per Item= 41.4; H-index= 99
 Google Scholar (27 Oct 2021) Total citations = 67673; i10-index= 565; H-index= 118;
 ORC-ID: 0000-0002-6269-1543 Web of Science ResearcherID: C-9073-2012